Effects of cyclodextrin in two patients with Niemann-Pick Type C disease

Mol Genet Metab. 2013 Jan;108(1):76-81. doi: 10.1016/j.ymgme.2012.11.005. Epub 2012 Nov 15.


Niemann-Pick Type C disease (NPC) is an autosomal recessive lysosomal storage disorder characterized by progressive neurological deterioration. Currently, there are no effective treatments for NPC, although miglustat has shown some effectiveness in stabilizing neurological status in juvenile-onset NPC patients. Recent studies have demonstrated the efficacy of hydroxypropyl-β-cyclodextrin (HPB-CD) in NPC mice. Herein, we describe the effects of HPB-CD in two patients with NPC. The two patients received HPB-CD infusions twice (Patient 2) or thrice (Patient 1) weekly, starting with a dose of 80 mg/kg per dose that was increased gradually to 2g/kg per dose (Patient 2) or 2.5 g/kg per dose (Patient 1). Although HPB-CD did not improve the neurological deficits in either patient, it was partially effective in improving hepatosplenomegaly and central nervous system dysfunction, especially during the first 6 months of treatment. No adverse effects were observed over the course of treatment, although Patient 1 exhibited transient cloudiness of the lungs with fever after 2 years. For more effective treatment of NPC patients with HPB-CD, it is necessary to improve drug delivery into the central nervous system.

Publication types

  • Case Reports

MeSH terms

  • 2-Hydroxypropyl-beta-cyclodextrin
  • Adolescent
  • Child, Preschool
  • Female
  • Humans
  • Niemann-Pick Disease, Type C / drug therapy*
  • beta-Cyclodextrins / therapeutic use*


  • beta-Cyclodextrins
  • 2-Hydroxypropyl-beta-cyclodextrin